14465 results for "PLOS+ONE+Pennsylvania+German+ACS+language+code+pdc+open+access+study"

in 19.30 milliseconds.

• Data access committee DMDMex dataset

  Dac EGAC00001001871

• Keratoconus MIPS Data Access Committee

  Dac EGAC00001001883

• IMpower133 Data Access Committee

  Dac EGAC00001001932

• HNSCC Data Access Commitee

  Dac EGAC00001001935

• TKI-BTRP Data Access Committee

  Dac EGAC00001001938

• Tumor Samples Data Access Committee

  Dac EGAC00001001976

• DMP Data Access Commitee

  Dac EGAC00001001996

• Termeer Center Data Access Committee

  Dac EGAC00001002015

• bladder cancer data access commitee

  Dac EGAC00001002016

• Pinggu Metagenomics Data Access Committee

  Dac EGAC00001002023

• Maastricht MIBS data access commitee

  Dac EGAC00001002029

• CRCINA Data Access Commitee

  Dac EGAC00001002045

• Extreme Phenotypes Data access commitee

  Dac EGAC00001002055

• Wits Data Access Committee

  Dac EGAC00001002087

• UKM, Data Access Committee

  Dac EGAC00001002105

• CCHT Data Access Commitee

  Dac EGAC00001002132

• Retinal Dystrophy Data Access Committee

  Dac EGAC00001002161

• Data Access Committee for EGAS00001005426

  Dac EGAC00001002194

• LU Hematogenomics Data Access Commitee

  Dac EGAC00001002196

• Varn Lab Data Access Committee

  Dac EGAC00001002214

• KIR imputation data access committee

  Dac EGAC00001002216

• CRMY team data access committee

  Dac EGAC00001002249

• Data Access Committee for cfMeDIP

  Dac EGAC00001002250

• Tumor Thrombus data access committee

  Dac EGAC00001002272

• LEBAO Data access committee

  Dac EGAC00001002280

• VHIR Data Access Committee

  Dac EGAC00001002332

• Australian Genomics Data Access Commitee

  Dac EGAC00001002300

• LU Hematogenomics Data Access Commitee

  Dac EGAC00001002348

• Medulloblastoma cfDNA Data Access Commitee

  Dac EGAC00001002368

• DIAMOND Prostate Data Access Commitee

  Dac EGAC00001002407

• Cancer Team Data Access Committee

  Dac EGAC00001002449

• Data access committee of IMPC

  Dac EGAC00001002468

• GINS3 RNAseq Data Access Committee

  Dac EGAC00001002540

• Data access committee for FL

  Dac EGAC00001002552

• Fudan University Data Access Committee

  Dac EGAC00001002611

• Smith Lab Data Access Committee

  Dac EGAC00001002615

• Walker Lab Data Access Committee

  Dac EGAC00001002621

• PBMC genotypes Data Access Commitee

  Dac EGAC00001002633

• Pitroda Lab Data Access Comittee

  Dac EGAC00001002650

• SI-NET Data Access Committee

  Dac EGAC00001002701

• Sputum Metagenome Data Access Committee

  Dac EGAC00001002757

• Spatial MI Data Access Commitee

  Dac EGAC00001002721

• VIB-UZL Data Access Committee

  Dac EGAC00001002724

• Fudan University Data Access Committee

  Dac EGAC00001002736

• UKM, Data Access Committee

  Dac EGAC00001002755

• HiFi Project Data Access Commitee

  Dac EGAC00001002803

• IDIBELL Access Commitee

  Dac EGAC00001002816

• IgAN-tGBM Data Access Commitee

  Dac EGAC00001002821

• ADPKD Data Access Commitee 1

  Dac EGAC00001002838

• ITER-HUNSC Data Access Committee

  Dac EGAC00001002839

• SCA3_RNA-Seq Data Access Committee

  Dac EGAC00001002840

• Cancer Team Data Access Committee

  Dac EGAC00001002891

• Celtic Fire Data Access Commitee

  Dac EGAC00001002918

• PGDx EGA Data Access Committee

  Dac EGAC00001002922

• KiCS Data Access Committee

  Dac EGAC00001002930

• KiCS Data Access Committee

  Dac EGAC00001002935

• KiCS Data Access Committee

  Dac EGAC00001002936

• Iberian Roma Data Access Commitee

  Dac EGAC00001002958

• CirDNA sWGS Data Access Commitee

  Dac EGAC00001002965

• Methylation Atlas Data Access Committee

  Dac EGAC00001002983

• UCLA WGS data access Committee

  Dac EGAC00001003012

• Clinical Research Data Access Commitee

  Dac EGAC00001003052

• OPTIMISTIC team Data Access Commitee

  Dac EGAC00001003066

• PDAC PDx Data Access Committee

  Dac EGAC00001003139

• LFS Data Access Committee

  Dac EGAC00001003154

• Ludwig Agora Data Access Committee

  Dac EGAC00001003160

• MRC Prion Unit Data Access Committee

  Dac EGAC01000000007

• Data Access Committee for EGAS00001007298

  Dac EGAC00001003422

• Dual ST dataset access committee

  Dac EGAC00001002635

• The AGGA Data Access Committee

  Dac EGAC00001003019

• Sarcoidosis Baseline Data Access Committee

  Dac EGAC00001003072

• Cerebral Palsy Data Access Commitee

  Dac EGAC00001003068

• Data Access Committee for EGAS00001007299

  Dac EGAC00001003268

• NeuroCoV Data Access Committee

  Dac EGAC00001002776

• Radarstudy Data Access Committee

  Dac EGAC00001003289

• Hubrecht Institute Data Access Commitee

  Dac EGAC00001003003

• SECRETO Oral Data Access Committee

  Dac EGAC00001003449

• Sottorivalab data access committee

  Dac EGAC00001003184

• DIPG THU Data Access Committee

  Dac EGAC00001002169

• EPIC Repeatability Data Access Committee

  Dac EGAC00001003201

• NSCLC Team Data Access Committee

  Dac EGAC00001002258

• DFCI cHL Data Access Commitee

  Dac EGAC00001003432

• Human Heart Data Access Committee

  Dac EGAC50000000413

• Beggs Lab Data Access Committee

  Dac EGAC00001001819

• Inform-Lynch-Syndrome-Access

  Dac EGAC00001003315

• EMBARCAM BC360 PROJECT Data Access Committee

  Dac EGAC00001003517

• Personalis, Inc. Data Access Committee

  Dac EGAC50000000325

• BIDMC Proteogenomics Data Access Committee

  Dac EGAC50000000386

• BIOCLOCK Data Access Committee

  Dac EGAC00001003573

• Rapid Acceleration of Diagnostics - Digital Health Technologies (RADx-DHT): Large Scale Flu Surveillance Study (LSFS)

  The purpose of this study was to better understand behavioral and physiological functioning in relation to recent self-reported influenza and influenza-like-illness (ILI), including coronavirus disease (COVID-19). Over 65,000 Achievement members responded to a weekly one-click survey asking if they had experienced ILI within the previous 7-day period. If they responded no, they were given the option to complete a survey about their risk factors and behavior. If they responded yes, they were given the option to complete a survey asking about the specifics of the incident. Participants were also asked to sync their wearable activity trackers and health apps in order for researchers to better understand changes in behavioral and physiological outcomes related to self-reported ILI experiences.DOI: https://rapids.ll.mit.edu/10.57895/fkth-d352

  Study phs002539

• DNA Replication Timing Alterations in Genetic Diseases

  This study contains a collection of lymphoblastoid cell line (LCL) and induced pluripotent stem cell (iPSC) whole genome sequencing from individuals with an without a diagnosed genetic disease. Several types of genetic diseases are included such as translocations, repeat expansions, and heritable or spontaneous mutations of genes. We used the whole genome sequencing to generate DNA replication timing profiles for these individuals and compared the profiles of diseased individuals to presumed healthy samples. We aimed to identify replication timing alteration linked to a specific genetic disease and therefore elucidate trans-acting factors of DNA replication timing. We found that replication timing was highly consistent across almost all diseased samples. Only one genetic disease, a mutation in MCM10, demonstrated an altered profile of replication timing.

  Study phs002597

• Genentech whole genome and transcriptome sequencing of four hepatocellular carcinoma patients

  Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). In this study we sequenced the whole genome (~80X) and transcriptome of tumor and non-tumor samples from four HCC patients and identified over two hundred HBV integration sites. We found significant clonal expansion of HBV-integrated hepatocytes specifically in the tumor samples. We observed a diverse collection of genomic perturbations near viral integration sites, including gene disruption, viral promoter-driven human transcription, viral-human transcript fusion and DNA copy number alteration. We also sequenced one patient at ultra-high coverage (~240X) to build the most comprehensive HBV-integration landscape yet attempted. Our data suggest that the viral integration significantly expands carcinogenic opportunities in HBV-infected individuals.

  Study phs000384

• Clonal tracing with somatic epimutations reveals dynamics of blood aging

  In this study, we generated comprehensive single-cell multi-omic datasets from bone marrow samples collected from 13 donors spanning a wide age range. We applied the scTAMseq protocol to profile DNA methylation and nuclear mutations obtained from 7 total bone marrow aspirates (donors A.1-A.7) and 6 CD34+-enriched bone marrow samples ((donors B.1-B.5 & X.1). Complementary surface marker expression data were acquired by integrating CITE-seq into the scTAMseq workflow (scTAMseq_prot). Targeted RNA sequencing (scTAMARA_rna) was performed alongside scTAMARA_DNA on one CD34+-enriched sample (X.1). Additionally, a dedicated mitochondrial panel (TAMITO_seq) was employed on a peripheral blood sample from a healthy donor (X.2) to assess mitochondrial heterogeneity and facilitate lineage tracing.

  Study EGAS00001008056

• Fixation effects on variant-calling in a clinical resequencing panel

  Formalin fixation is the standard method for preservation of tissue for diagnostic purposes, including pathological review and molecular assays. However, this method is known to cause artifacts that can affect the accuracy of molecular genetic tests. We assessed the applicability of alternative fixatives to determine whether these perform significantly better on next-generation sequencing assays, and whether adequate morphology is retained for primary diagnosis, in a prospective study using a clinical-grade laboratory-developed targeted resequencing assay. We examined and quantified several parameters relating to sequencing quality and variant-calling from tumor and normal colon epithelial tissues. We identify one alterative fixative, Sakura Universal Molecular Fixative that suppresses many formalin-related artifacts while retaining adequate morphology for pathological review.

  Study EGAS00001003507

• Single cell transcriptomics to characterize the tumor microenvironment of prostate cancer fusion biopsies

  The primary objective of this study was to characterize the tumor microenvironment in fusion-guided transperineal biopsy samples from patients undergoing PC diagnosis. For each patient, one biopsy was taken from a suspected tumor region and another from a non-suspicious area, which were later classified as high- or low-tumorigenicity based on anatomopathological analysis. Using scRNA-seq data, we performed cancer-oriented cell annotation, differential expression analysis, and functional pathway enrichment studies across key cellular subpopulations. Additionally, differential abundance analysis was conducted to identify cell groups representative of different tumorigenicity levels. Finally, classification models were developed using gene expression data to differentiate high- vs. low-tumorigenicity samples, with the long-term goal of establishing a diagnostic classifier for PC stratification.

  Study EGAS50000000888

• International Multi-Center ADHD Gene Project (IMAGE) II Case Sample

  This sample represents a collection of cases across a range of sites. All of these samples were ascertained for ADHD with most meeting criteria for combined type ADHD. The collection sites span Europe and America. Further details on the source and inclusion and exclusion information can be found in Neale et al. "Case-Control Genome-Wide Association of Attention-Deficit / Hyperactivity Disorder" J Am Acad Child Adolesc Psychiatry. 2010 September; 49(9): 906-920 PMID20732627. For online access to this manuscript see: PMC2928577.

  Study phs000407

• INCLUDE: Human Trisome Project

  The INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project is an NIH-wide collaboration that seeks to improve health and quality-of-life for people with Down syndrome. The INCLUDE Project Data Coordinating Center and partners created the INCLUDE Data Hub, a centralized data resource that allows access to large-scale clinical and multi-omics datasets specific to Down syndrome and supports collaborative, cloud-based analysis to accelerate scientific discoveries related to Down syndrome and its co-occurring conditions.

  Study phs002981

• Integrated Exome and RNA Sequencing of Dedifferentiated Liposarcoma

  Multiomics analysis of rare cancers to identify genetic alterations related with pathogenesis and prognosis. To identification of genetics alterations of Dedifferentiated liposarcoma, DNAs and RNAs were extracted from dedifferentiated liposarcoma and paired non-cancer (normal) tissues. NGS libaraies were prepared by using Agilent SureSelect XT Human All Exon V5 + IncRNA kit for whole exome sequencing (WES) and TruSeq Stranded mRNA Prep kit or TruSeq RNA Access Library Prep kit (RNA seq). Sequencing was perfomred by Illumina HiSeq 2500.

  Study JGAS000177

• Analysis of genomic alterations in dedifferentiated liposarcoma

  Multiomics analysis of rare cancers to identify genetic alterations related with pathogenesis and prognosis. To identification of genetics alterations of Dedifferentiated liposarcoma, DNAs and RNAs were extracted from dedifferentiated liposarcoma and paired non-cancer (normal) tissues. NGS libaraies were prepared by using Agilent SureSelect XT Human All Exon V5 + IncRNA kit for whole exome sequencing (WES) and TruSeq Stranded mRNA Prep kit or TruSeq RNA Access Library Prep kit (RNA seq). Sequencing was perfomred by Illumina HiSeq 2500.

  Study JGAS000182

• PROGRESS/ELEMENT DNA Methylation Study

  An extension to the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) birth cohort of Mexico City, the Programming Research in Obesity, GRowth, Environment and Social Stress (PROGRESS) Cohort is an ongoing longitudinal pre-birth cohort, established in 2006 in Mexico City, partnering Icahn School of Medicine at Mount Sinai with Harvard University and the National Institute of Public Health in Mexico, which was designed to study the effects of prenatal exposure to toxic metals, air pollution, phthalates, and stress on childhood development. Pregnant women of 18 years of age and older, pregnant for less than 20 weeks of gestation, had no documentation of heart or kidney disease, no use of steroids or anti-epilepsy drugs, no daily alcohol consumption, had telephone access, and planned to live in Mexico city for the following 3 years, and receiving care through the Mexican Social Security System were initially enrolled (n=1,054). In addition to clinical, demographic and exposure data collected, cord blood was collected to interrogate DNA methylation across the genome for over 300 mother-child dyads. Clinical assessments and exposures were captured during several life stages, including prenatal, infant (0-1 year), youth (1-18 years), and adulthood (mother). The PROGRESS cohort added well-documented phenotyping of children for obesity, metabolic dysfunction, respiratory outcomes, and cardiovascular outcomes, as well as measures of air pollutant, personal care/consumer product, non-chemical stress, and metal mixture exposures. No clinical trials were conducted in this cohort. The data collected in this study should provide a unique resource to investigate DNA methylation as it relates to several environmental exposures and adverse cardiometabolic and neurocognitive health in mothers and children from a prospective birthing cohort. For access to demographic, clinical, and exposure data please directly contact study principal investigators.

  Study phs002754